Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

6.410 -0.470 (-6.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,776
Open 6.880
Bid (Size) 6.120 (7)
Ask (Size) 6.650 (10)
Prev. Close 6.880
Today's Range 6.350 - 6.880
52wk Range 2.315 - 9.900
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?
In a financial landscape increasingly dominated by the towering valuations of large-cap technology giants, a quieter, yet potentially profound, narrative is unfolding within the small-cap segment of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+32.4%
+32.4%
1 Month
-17.9%
-17.9%
3 Month
+0.9%
+0.9%
6 Month
+73.2%
+73.2%
1 Year
-34.2%
-34.2%

More News

Read More
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday?
Via Chartmill
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Uncovering Potential: Fulcrum Therapeutics's Earnings Preview
Via Benzinga
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday?
Via Chartmill
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
Via Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
The current price of Fulcrum Therapeutics, Inc. - Common Stock is 6.410
When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 08/25/25 04:00 PM ET
What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 395.88M
How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
Fulcrum Therapeutics, Inc. - Common Stock has 396M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.